Prelude Therapeutics annual capital expenditures (capex)
2019
2020
2021
2022
2023
2024
2025
Prelude Therapeutics Capital Expenditures (CapEx) Growth & History (PRLD)
Prelude Therapeutics's capital expenditures (capex) was $67,000 for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $67,000 | −$697,000 | −91.23% |
| 2024 | 2024-12-31 | $764,000 | −$2.7M | −78.25% |
| 2023 | 2023-12-31 | $3.5M | $494,000 | +16.36% |
| 2022 | 2022-12-31 | $3.0M | $696,000 | +29.96% |
| 2021 | 2021-12-31 | $2.3M | $1.7M | +274.07% |
| 2020 | 2020-12-31 | $621,000 | −$159,000 | −20.38% |
| 2019 | 2019-12-31 | $780,000 | — | — |
Prelude Therapeutics quarterly capital expenditures (capex)
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | −$20,000 | — |
| Q1 2026 | 2026-03-31 | $0 | −$47,000 | — |
| Q4 2025 | 2025-12-31 | $0 | −$53,000 | — |
| Q3 2025 | 2025-09-30 | $0 | −$63,000 | — |
| Q2 2025 | 2025-06-30 | $20,000 | −$339,000 | −94.43% |
| Q1 2025 | 2025-03-31 | $47,000 | −$242,000 | −83.74% |
| Q4 2024 | 2024-12-31 | $53,000 | −$1.1M | −95.31% |
| Q3 2024 | 2024-09-30 | $63,000 | −$528,000 | −89.34% |
| Q2 2024 | 2024-06-30 | $359,000 | −$624,000 | −63.48% |
| Q1 2024 | 2024-03-31 | $289,000 | −$521,000 | −64.32% |
| Q4 2023 | 2023-12-31 | $1.1M | $736,000 | +187.28% |
| Q3 2023 | 2023-09-30 | $591,000 | −$325,000 | −35.48% |
| Q2 2023 | 2023-06-30 | $983,000 | $225,000 | +29.68% |
| Q1 2023 | 2023-03-31 | $810,000 | −$142,000 | −14.92% |
| Q4 2022 | 2022-12-31 | $393,000 | $96,000 | +32.32% |
| Q3 2022 | 2022-09-30 | $916,000 | $257,000 | +39.00% |
| Q2 2022 | 2022-06-30 | $758,000 | $377,000 | +98.95% |
| Q1 2022 | 2022-03-31 | $952,000 | −$34,000 | −3.45% |
| Q4 2021 | 2021-12-31 | $297,000 | −$32,000 | −9.73% |
| Q3 2021 | 2021-09-30 | $659,000 | $489,000 | +287.65% |
| Q2 2021 | 2021-06-30 | $381,000 | $339,000 | +807.14% |
| Q1 2021 | 2021-03-31 | $986,000 | $906,000 | +1132.50% |
| Q4 2020 | 2020-12-31 | $329,000 | — | — |
| Q3 2020 | 2020-09-30 | $170,000 | — | — |
| Q2 2020 | 2020-06-30 | $42,000 | — | — |
| Q1 2020 | 2020-03-31 | $80,000 | — | — |
Prelude Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Prelude Therapeutics's capital expenditures (capex) decreased from $621,000 to $67,000, a change of −$554,000. The latest reported quarter, Q2 2026, shows $0.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...